Skip to main content
. 2001 Jan;21(2):414–424. doi: 10.1128/MCB.21.2.414-424.2001

FIG. 1.

FIG. 1

Enhanced expression of IGFBP-1 in IL-6 transgenic mice, in IL-6+/+ livers posthepatectomy, and after IL-6 treatment. (A) Delayed expression of IGFBP-1 mRNA in IL6−/− livers posthepatectomy (PH). RNA was prepared from IL-6−/− and IL-6+/+ livers at the indicated times after hepatectomy. RNA (10 μg) was gel electrophoresed and probed with nick-translated rat IGFBP-1 cDNA probe. β2-Microglobulin (β2M) was used as a normalizing control. This Northern blot is representative of three. (B) Diminished serum IGFBP-1 protein level in IL-6−/− livers posthepatectomy. Five-microliter aliquots of serum were fractionated on an SDS–12% polyacrylamide gel, blotted, and incubated with the IGFBP-1 antibody. (C) Elevated expression of IGFBP-1 mRNA in IL-6 transgenic and IL-6/IL-6 soluble receptor (IL-6/sIL-6) double-transgenic mice. C, control animal. (D) Induction of hepatic IGFBP-1 mRNA after 16-h (overnight [O/N]) fast or 1 to 2 h after IL-6 injection. The animals were injected subcutaneously with rhIL-6 (1 mg/kg) for 1 or 2 h. (E) Induction of serum IGFBP-1 after overnight fasting or 1 to 2 h after IL-6 treatment.